FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Cahill Brian Joseph						2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [ EGRX ]									ck all app Direc	licable)	ng Pe	rson(s) to Is 10% Ov Other (s	vner	
(Last)	(Fir	st) (N	/liddle)									_ ^	belov	,		below)				
C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BOULEVARD, SUITE 315						3. Date of Earliest Transaction (Month/Day/Year) 01/29/2021										Chief Fina	ncial	Officer		
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind	6. Individual or Joint/Group Filing (Check Applicable					
, ,	WOODCLIFF NJ 07677													1 ′	X Form filed by One Reporting Person					
LAKE	INJ		7677												Form filed by More than One Reporti Person				orting	
(City)	(St	ate) (Z	<u>Z</u> ip)																	
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	3ene	ficial	ly Own	ed				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Exec if an	ution [	eemed ution Date, :h/Day/Year)					es Acquired (A Of (D) (Instr. 3,			ies cially Following	Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D) Pri		rice	Transa	Reported Transaction(s) (Instr. 3 and 4)				
Common Stock 01/29/2					2021				F <sup>(1)</sup>		637	Г	\$	646.67	18	8,666		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		D S (I	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	\ \ v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amor or Numi of Share	ber						

## **Explanation of Responses:**

1. Represents shares withheld to satisfy withholding tax obligations

## Remarks:

/s/ Brian Cahill

02/02/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.